Trial · NCT00920816
Participant flow20
How many started, completed or left each group, period by period.
1 to 20 of 20
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Axitinib (First-line Participants) | 192 | |
| Overall Study | STARTED | Sorafenib (First-line Participants) | 96 | |
| Overall Study | STARTED | Axitinib (Second-line Participants) | 135 | |
| Overall Study | STARTED | Sorafenib (Second-line Participants) | 69 | |
| Overall Study | Treated | Axitinib (First-line Participants) | 189 | |
| Overall Study | Treated | Sorafenib (First-line Participants) | 96 | |
| Overall Study | Treated | Axitinib (Second-line Participants) | 135 | |
| Overall Study | Treated | Sorafenib (Second-line Participants) | 69 | |
| Overall Study | Participants From China (Excluded From Safety Analysis) | Axitinib (First-line Participants) | 16 | |
| Overall Study | Participants From China (Excluded From Safety Analysis) | Sorafenib (First-line Participants) | 8 | |
| Overall Study | Participants From China (Excluded From Safety Analysis) | Axitinib (Second-line Participants) | 124 | |
| Overall Study | Participants From China (Excluded From Safety Analysis) | Sorafenib (Second-line Participants) | 64 | |
| Overall Study | COMPLETED | Axitinib (First-line Participants) | 0 | |
| Overall Study | COMPLETED | Sorafenib (First-line Participants) | 0 | |
| Overall Study | COMPLETED | Axitinib (Second-line Participants) | 0 | |
| Overall Study | COMPLETED | Sorafenib (Second-line Participants) | 0 | |
| Overall Study | NOT COMPLETED | Axitinib (First-line Participants) | 192 | |
| Overall Study | NOT COMPLETED | Sorafenib (First-line Participants) | 96 | |
| Overall Study | NOT COMPLETED | Axitinib (Second-line Participants) | 135 | |
| Overall Study | NOT COMPLETED | Sorafenib (Second-line Participants) | 69 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00920816/flow